Tonix Wins Patent in China

Tonix Wins Patent in China

By: Dylan Sikes – AllPennyStocks.com News

Thursday, June 13, 2019

Good things are happening these days for New York-based Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP). Thursday, the company revealed that the China National Intellectual Property Administration issued Chinese Patent No. ZL 201480024011.1, a development dating back to April. 

This patent, “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride,” is directed to a unique eutectic that characterizes TNX-102 SL, and claims pharmaceutical compositions containing that eutectic and methods of making those compositions. 

TNX-102 SL is being developed as a treatment for three indications: post-traumatic stress disorder, fibromyalgia and agitation in Alzheimer’s disease.  Marketed oral cyclobenzaprine products are indicated for the relief of muscle spasm. 

Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat psychiatric, pain and addiction conditions, and biological products to improve biodefense through potential medical counter-measures

Shares gained six cents, or 3.8%, late Thursday morning, to $1.64, on volume of 175,000 shares

 


Copyright © 2019 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon

Other Penny Stock Movers

Canadian Inflation Moves Up as Expected But Easing Underlying Pressures Boost Hopes of June Rate Cut
Key Executive Appointment Sends Small Cap Higher
Key Press Release Sends Small Cap Soaring Premarket
Most Popular
FREE Newsletter
AllPennyStocks.com Favorites


Back to Top